Skip to main content

Table 1 Demographic and clinical characteristics in the total vaccinated cohort

From: Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

  QIV TIV-Vic TIV-Yam
  N = 3036 N = 1010 N = 610
Mean age, years (SD; median; range) 57.9 (17.7; 64.0; 18.0–92.0) 58.1 (17.8; 64.0; 18.0–92.0) 58.1 (17.9; 65.0; 18.0–90.0)
Sub-groups: mean age, years (SD, median) 43.5 (13.58; 44.0) 43.7 (13.84; 44.0) 43.5 (14.01; 46.0)
  18–64 years 72.3 (5.45; 71.0) 72.5 (5.53; 71.0) 72.4 (5.39; 72.0)
  ≥65 years    
Male, n (%) 1291 (42.5) 462 (45.7) 267 (43.8)
Hispanic/Latino ethnicity, n (%) 134 (4.4) 47 (4.7) 25 (4.1)
Not Hispanic/Latino ethnicity, n (%) 2902 (95.6) 963 (95.3) 585 (95.9)
Geographic ancestry 2078 (68.4) 699 (69.2) 414 (67.9)
  European heritage / Caucasian 22 (0.7) 7 (0.7) 4 (0.7)
  Arabic/north American heritage / Caucasian 805 (26.5) 270 (26.7) 162 (26.5)
  Asian 106 (3.5) 26 (2.6) 21 (3.4)
  African heritage / African American 6 (0.2) 2 (0.2) 3 (0.5)
  American Indian or native Alaskan 2 (0.1) 0 0
  Native Hawaiian or other pacific islander 17 (0.6) 6 (0.6) 6 (1.0)
  Other    
Medical history, n (%) 533 (17.56) 153 (15.15) 106 (17.38)
  Cardiovascular disease 457 (15.05) 129 (12.77) 89 (14.59)
  Diabetes 293 (9.65) 104 (10.30) 57 (9.34)
  Chronic respiratory disease 117 (3.85) 39 (3.86) 26 (4.26)
  Cancer 76 (2.50) 17 (1.68) 13 (2.13)
  Cerebrovascular disease 60 (1.98) 23 (2.28) 13 (2.13)
  Chronic hepatic disease 43 (1.42) 11 (1.09) 6 (0.98)
  Chronic renal disease    
Received seasonal influenza vaccination in at least one of previous three seasons, n (%) 2395 (78.9) 788 (78.0) 483 (79.2)
Received A/H1N1pdm09 vaccination during the previous season 848 (27.9) 289 (28.6) 165 (27.0)
  1. QIV inactivated quadrivalent influenza vaccine, SD standard deviation, TIV-Vic inactivated trivalent influenza vaccine Victoria lineage B strain, TIV-Yam inactivated trivalent influenza vaccine Yamagata lineage B strain, Excluding hypertension.
\